SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Bellicum Pharmaceuticals, Inc. BLCM NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Bellicum Pharmaceuticals, Inc. (BLCM) is a Biotechnology company in the Healthcare sector, currently trading at $0.07. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Financials: revenue is $2M, +323.7%/yr average growth. Net income is $25M (loss), growing at -26.2%/yr. Net profit margin is -1664.9% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $0 against $2M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 6.31 (strong liquidity). Debt-to-assets is 0%. Total assets: $24M.

Analyst outlook: 9 / 9 analysts rate BLCM as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 46/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

BLCM SharesGrow Score Overview

56/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 46/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BLCM

No analyst coverage available for this stock.

BLCM: +323.7%/yr revenue is, -26.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet BLCM: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 6.31 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

BLCM: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.

View details →

Analyst outlook: 9 / 9 analysts rate BLCM as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

BLCM: Net profit margin is -1664.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.06-1.31

Volume6.06K

Avg Volume (30D)28.58K

Market Cap$778.33K

Beta (1Y)1.38

Share Statistics

EPS (TTM)-0.81

Shares Outstanding$30.83M

IPO Date2014-12-18

Employees13

CEODavid M. Maggio

Financial Highlights & Ratios

Revenue (TTM)$1.5M

Gross Profit$1.5M

EBITDA$-26.98M

Net Income$-24.97M

Operating Income$-26.98M

Total Cash$21.84M

Net Debt$-21.84M

Total Assets$23.82M

Price / Earnings (P/E)-0.1

Price / Sales (P/S)0.52

Analyst Forecast

Rating ConsensusBuy

Analysts Covering9

Buy 100% Hold 0% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS0794814048

Price Chart

BLCM

Bellicum Pharmaceuticals, Inc. ↗ · NASDAQ Capital Marke

Healthcare • Biotechnology

0.06 52WK RANGE 1.31

People Also View

Adaptimmune Therapeutics plc

Atara Biotherapeutics, Inc.

Calithera Biosciences, Inc.

Eli Lilly and Company

Johnson & Johnson

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message